Fukuda Y, Yamamoto I, Okui M, Tonokatsu Y, Shimoyama T
Department of Internal Medicine IV, Hyogo College of Medicine, Japan.
J Clin Gastroenterol. 1995;20 Suppl 2:S132-5. doi: 10.1097/00004836-199506002-00036.
We investigated the eradication and recurrence rate of Helicobacter pylori-infected gastric ulcer patients by combination therapies. Eighty-six H. pylori-positive gastric ulcer patients were assigned randomly to one of seven groups: I, omeprazole 20 mg (n = 9); II, lansoprazole (LPZ) 30 mg (n = 16); III, LPZ 30 mg plus plaunotol 480 mg (n = 13); IV, LPZ 30 mg plus ecabet sodium 2 g (n = 11); V, LPZ 30 mg plus clarithromycin 600 mg (the first 2 weeks; n = 11); VI, LPZ 30 mg plus plaunotol 480 mg plus clarithromycin 600 mg (the first 2 weeks; n = 13); and VII, LPZ 30 mg plus ecabet sodium 2 g plus amoxicillin 1,500 mg (the first 2 weeks; n = 13). All therapy was for 8 weeks except where otherwise noted. H. pylori eradication rates as diagnosed by culture, histology, urease test, and [13C]urea breath test 4 weeks after stopping therapy were 0, 0, 8, 45, 6, 46, and 62%, respectively, in groups I-VII. No patient achieving H. pylori eradication suffered recurrence. The combination therapies with proton pump inhibitors in addition to antibiotics and antiulcer agents are safe and effective in H. pylori eradication.
我们通过联合疗法研究了幽门螺杆菌感染的胃溃疡患者的根除率和复发率。86例幽门螺杆菌阳性的胃溃疡患者被随机分为七组之一：I组，奥美拉唑20毫克（n = 9）；II组，兰索拉唑（LPZ）30毫克（n = 16）；III组，LPZ 30毫克加普劳诺托480毫克（n = 13）；IV组，LPZ 30毫克加依卡倍特钠2克（n = 11）；V组，LPZ 30毫克加克拉霉素600毫克（前2周；n = 11）；VI组，LPZ 30毫克加普劳诺托480毫克加克拉霉素600毫克（前2周；n = 13）；VII组，LPZ 30毫克加依卡倍特钠2克加阿莫西林1500毫克（前2周；n = 13）。除另有说明外，所有治疗均持续8周。停药4周后，通过培养、组织学、尿素酶试验和[13C]尿素呼气试验诊断的I - VII组幽门螺杆菌根除率分别为0%、0%、8%、45%、6%、46%和62%。实现幽门螺杆菌根除的患者均未复发。质子泵抑制剂联合抗生素和抗溃疡药物的联合疗法在根除幽门螺杆菌方面安全有效。
